ERBB2 and breast carcinoma: The data suggested modulation of TGF-β/Smad pathway by small molecule inhibitors, such as A83-01, may provide a novel approach to therapeutic intervention of TGF-β-initiated pathway interaction and EMT in breast cancer, especially in HER2-overexpressing breast cancer.